Navigation Links
Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
Date:8/21/2008

CORAL GABLES, Fla., Aug 21 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported that animal data from a new study sponsored by scientists at the U.S. Department of Energy's Brookhaven National Laboratory appears to demonstrate that taking vigabatrin leads to rapid weight loss and reduced food intake. The data was published online as of August 20, 2008 in the journal Synapse, a prestigious peer-reviewed neuroscience publication.

Catalyst Pharmaceutical Partners is currently evaluating the use of CPP-109, its version of vigabatrin, for the treatment of both cocaine and methamphetamine addiction. Two FDA-approved U.S. Phase II clinical trials are currently ongoing. CPP-109 is an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release.

According to the study published in Synapse, a total of 50 adolescent and adult animals, all genetically bred to be obese, were assigned to either a control group or groups that received vigabatrin at various dose levels and were monitored for up to 40 days. The controls received daily salt water (saline) injections, while those in the study groups received up to 300 milligrams of vigabatrin per day. All animals received injections for two, 7-13 day periods, with breaks in between.

At the end of the 40 day period, all animals receiving vigabatrin weighed significantly less than the control subjects. In fact, those animals that were bred to be obese experienced a loss of up to 19 percent of their total weight, while non-obese animals lost 12 to 20 percent of their total weight following short-term treatment with vigabatrin. Amy DeMarco of Brookhaven led the study working in the laboratory of Brookhaven Lab sen
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
2. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
3. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
4. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
5. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
6. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
7. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
10. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
11. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... has acquired the approved abbreviated new drug application ... and 150mg, previously marketed by Teva Pharmaceuticals.  According ... product was approximately $39 million in 2014.   ... and CEO of ANI Pharmaceuticals, stated, "This acquisition ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gl7m98/japan_pharma ) ... Outlook 2015: Year to Watch out for Authorized Generics ... their offering. The new pricing system ... -2014 (Annexure 1) is a game changer initiative. It ... innovator. The most of the companies are revalidating their ...
(Date:3/5/2015)... VIENNA , March 5, 2015 ... announce the new generation of OASIS *    ... with enhanced processing power will set a benchmark for ... overcome obstacles and prevent delays whilst optimizing workflow management ... quality, patient comfort and safety for imaging in Neurology, ...
Breaking Medicine Technology:ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 2Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 3
... NEW YORK, Nov. 29, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0693503/Medical-Devices---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics This ... from the following Asian countries: Azerbaijan, China, ...
... Uptake Medical® today announced the first commercial use of ... a patient with severe emphysema. The patient successfully underwent ... system for the treatment of severe emphysema that uses ... in the lung. The patient was treated by the ...
Cached Medicine Technology:Medical Devices - Asia 2Uptake Medical Announces First Commercial Use of InterVapor for Patients With Severe Emphysema 2Uptake Medical Announces First Commercial Use of InterVapor for Patients With Severe Emphysema 3
(Date:3/5/2015)... Testosterone lawsuits ( http://www.testosteronelawsuithub.com/ ) filed ... strokes and other serious cardiovascular events due to their ... forward in the federal multidistrict litigation now underway in ... a Case Management Order issued on March 3rd, the ... master pleadings in the proceeding. Among other things, the ...
(Date:3/5/2015)... 2015 On March 2, 2015, NBC ... on the Rise, Plastic Surgeons Say,” that comments on ... for Aesthetic Plastic Surgery and the American ... a year-over-year doubling of surgical butt augmentations performed in ... the article, this increase can be attributed to the ...
(Date:3/5/2015)... HMP Communications Holdings , ... education, announced today its acquisition of the ... medical conference designed for health care providers dedicated ... amputation due to vascular disorders. The 5-year-old ... publications and CME activities across therapeutic fields such ...
(Date:3/5/2015)... Venice, FL (PRWEB) March 05, 2015 ... their 15th annual listing of “Pros to Know” in ... announce that two members of MEBC’s leadership team were ... Rhodes were nominated and received this award due to ... use of innovative methods for meeting and resolving client ...
(Date:3/5/2015)... 2015 Leading nutritional supplement provider ... Sports Festival and Arnold Fitness EXPO in ... will host a display booth featuring free samples of ... its highly-popular, class-leading fat burner Synedrex. The company will ... that utilize its top-of-the-line supplements and miniature action figures ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Metabolic Nutrition Exhibiting at 2015 Arnold Sports Festival and Fitness EXPO This Week 2
... test by using EEG can predict whether a person ... by Leslie S. Prichep of the New York University School ... 44 patients and followed these people for a decade. The ... would develop dementia. ,Dementia is a brain disorder that causes ...
... research from the National Institute of Diabetes and Digestive and ... shown stabalisation of annual increases from 5 to 10 ... there is still a dramatic racial disparity. , ... than 1 percent since 1999, compared to an average 5 ...
... cancer vaccine trial against Melanoma which is a type ... vaccine developed by Antigenics.// The vaccine trial of Oncophage ... the required statistically significance results compared to prolongation in ... any better results compared to other cancer treatments. ...
... a near-pandemic condition that threatens millions with loss of ... atherosclerotic plaque in the arteries outside your heart.// Stem ... blood vessels and grow new ones thus restoring blood ... Ltd, a private, multinational company focuses on using stem ...
... inflammation according to scientists. Inflammation has a role to ... cardiovascular disease, diabetes, obesity, Alzheimer’s besides infections//. , ... said: “Practically every common disease involves an inflammation component,” ... Research (SFBR) in San Antonio., ,“So the discovery ...
... following ace cricketer Sachin Tendulkar's and several other players complaining ... the sports arena//. ,Tennis elbow, or lateral epicondylitis ... where the outer part of the elbow becomes painful and ... or a direct bang. The problem occurs following overuse of ...
Cached Medicine News:Health News:US Kidney Failure Rates show Stabilization After 20-Year Climb 2Health News:Tennis elbow not new among cricketers, say experts 2
... inhalers., ,ACE ensures prompt, effective delivery ... versatile design allows it to be used ... an endotracheal airway or resuscitation bag and ... be used in conjunction with an incentive ...
With ten colors available, Spectrums line of Color-Coded Fiberoptic Light Cables makes it easy to track by department....
... four models in proven halogen technology and ... find the right solution for every application: ... combination of two or three mobile lamps ... an on/off switch on the lamp housing, ...
Advanced Lighting System with Multi-Lamp Design providing Surgeon Focus Control and Extended, Variable Depth of Field over greater working distances. High Intensity, Cool Beam Temperature...
Medicine Products: